Tabula Rasa HealthCare (TRHC) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tabula Rasa HealthCare in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TRHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRHC, but not buy additional shares or sell existing shares.
View TRHC analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1-year price targets for Tabula Rasa HealthCare's stock. Their TRHC share price forecasts range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 22.9%.
View analysts price targets for TRHC or view top-rated stocks among Wall Street analysts.

Tabula Rasa HealthCare's stock was trading at $4.95 at the start of the year. Since then, TRHC shares have increased by 109.5% and is now trading at $10.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TRHC earnings forecast.

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.24. The company earned $90.04 million during the quarter, compared to the consensus estimate of $88.82 million.

24 employees have rated Tabula Rasa HealthCare Chief Executive Officer Calvin H. Knowlton, BScPharm, MDiv, PhD on Glassdoor.com. Calvin H. Knowlton, BScPharm, MDiv, PhD has an approval rating of 91% among the company's employees. This puts Calvin H. Knowlton, BScPharm, MDiv, PhD in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tabula Rasa HealthCare investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Adobe (ADBE), Micron Technology (MU), Boeing (BA), Salesforce (CRM), Intel (INTC) and Netflix (NFLX).

(TRHC) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,300,000 shares at $13.00-$15.00 per share. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Baird and Stifel were co-managers.

Tabula Rasa HealthCare trades on the NASDAQ under the ticker symbol "TRHC."

Shares of TRHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRHC stock can currently be purchased for approximately $10.37.

Tabula Rasa HealthCare (NASDAQ:TRHC) has a market capitalization of $280.61 million and generates $299.52 million in revenue each year. The company earns $-147,510,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

The company employs 1,027 workers across the globe.

Tabula Rasa HealthCare's mailing address is 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057. The official website for the company is www.tabularasahealthcare.com. The company can be reached via phone at (866) 648-2767 or via email at tabularasa@westwicke.com.